PRCT Stock Analysis: Buy, Sell, or Hold?
PRCT - PROCEPT BioRobotics Corporation Common Stock
$25.15
-0.21 (-0.83%)
▼
5d:
+0.32%
30d:
-5.31%
90d:
-20.06%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Apr 23, 2026
20d
Smart Money Accumulation
PRCT is down 4.7% this week, but smart money is accumulating calls. Top strike: $30 2026-05-15 with 325 OI. Call ratio: 100% View Scanner →
Strength: 7.4/10
Get Alerted When PRCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PRCT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PRCT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PRCT is currently trading at $25.15, which is considered fair relative to its 30-day fair value range of $24.77 to $27.50.
Technical Outlook: Technically, PRCT is in a strong downtrend. Immediate support is located at $24.10, while resistance sits at $27.08.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.44 (+20.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PRCT is in a strong downtrend. Immediate support is located at $24.10, while resistance sits at $27.08.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.44 (+20.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$24.77 -
$27.50
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($30.44)
Fair Price Analysis
30-Day Fair Range
$24.77 -
$27.50
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$24.10
Resistance Level
$27.08
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-28.72
Wall Street Target
$30.44
(+20.0%)
Revenue Growth (YoY)
11.9%
Profit Margin
-31.0%
Share & Embed Analysis
Last updated: April 02, 2026 3:23 PM ET
Data refreshes hourly during market hours. Next update: 4:23 PM
Data refreshes hourly during market hours. Next update: 4:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRCT showing a specific setup today?
Insider Activity (6 Months)
3
Buys
3
Sells
0
Net
NEUTRAL
Recent Transactions
Alaleh Nouri
SELL
3243 shares
2026-03-10
Antal Rohit Desai
BUY
98699 shares
2026-03-09
Alaleh Nouri
SELL
6892 shares
2026-03-06
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 61 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 62 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$354 | 52 HOLD |
